159 related articles for article (PubMed ID: 30671930)
41. Muir-Torre Syndrome Presenting as a Sebaceous Carcinoma of the Nasal Ala.
Coquillard C; Boustany A; DeCoster RC; Vasconez HC
Am Surg; 2019 Mar; 85(3):e115-e117. PubMed ID: 30947781
[No Abstract] [Full Text] [Related]
42. Mosaic Muir Torre Syndrome: Keratoacanthoma as a Piece of the Puzzle.
O'Brien A; Macfarlane S; Sommerlad M; Schirwani S
Am J Dermatopathol; 2024 Mar; 46(3):162-166. PubMed ID: 38170727
[TBL] [Abstract][Full Text] [Related]
43. Sebaceous tumours: a prototypical class of skin tumour for universal germline genetic testing.
Gallon R; Kibbi N; Cook S; Santibanez-Koref M; Jackson MS; Burn J; Rajan N
Br J Dermatol; 2021 Nov; 185(5):1045-1046. PubMed ID: 34050928
[No Abstract] [Full Text] [Related]
44. A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy.
Guo Z; Cai Y; Yin W; Huang J
Tumori; 2023 Dec; 109(6):NP27-NP31. PubMed ID: 37880978
[TBL] [Abstract][Full Text] [Related]
45. Sebaceous adenoma of the conjunctiva and caruncle: a clinicopathological report of three cases and literature review.
Dias MBB; Morales MC; Fernandes AG; Rigueiro M; Odashiro AN; Belfort Neto RM
Arq Bras Oftalmol; 2021; 85(2):174-177. PubMed ID: 34431898
[TBL] [Abstract][Full Text] [Related]
46. Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review.
Aziz S; O'Sullivan H; Heelan K; Alam A; McVeigh TP
Fam Cancer; 2023 Apr; 22(2):167-175. PubMed ID: 36418753
[TBL] [Abstract][Full Text] [Related]
47. The M2 macrophages infiltration of sebaceous tumors is linked to the aggressiveness of tumors but not to the mismatch repair pathway.
Frouin E; Alleyrat C; Godet J; Karayan-Tapon L; Sinson H; Morel F; Lecron JC; Favot L
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6445-6454. PubMed ID: 36763173
[TBL] [Abstract][Full Text] [Related]
48. A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.
Kientz C; Joly MO; Faivre L; Clemenson A; Dalac S; Lepage C; Chapusot C; Jacquot C; Schiappa R; Lebrun M
Hered Cancer Clin Pract; 2017; 15():6. PubMed ID: 28507641
[TBL] [Abstract][Full Text] [Related]
49. Update on the pathology, genetics and somatic landscape of sebaceous tumours.
Ferreira I; Wiedemeyer K; Demetter P; Adams DJ; Arends MJ; Brenn T
Histopathology; 2020 Apr; 76(5):640-649. PubMed ID: 31821583
[TBL] [Abstract][Full Text] [Related]
50. Muir-Torre Syndrome Presenting as Sebaceous Adenocarcinoma and Invasive MSH6-Positive Colorectal Adenocarcinoma.
Tulpule S; Ibrahim H; Osman M; Zafar S; Kanta R; Shypula G; Islam MA; Sen S; Yousif A
Case Rep Oncol; 2016; 9(1):95-9. PubMed ID: 26933426
[TBL] [Abstract][Full Text] [Related]
51. Muir-Torre Syndrome With a Frame-shift Mutation in the MSH2 Gene: A Rare Case Report and Literature Review.
Chen Q; Wang M; Xu Z; Wang M; Jin S; Tian S; Xiao S
Int J Gynecol Pathol; 2020 Mar; 39(2):136-140. PubMed ID: 32039937
[TBL] [Abstract][Full Text] [Related]
52. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018.
Cook S; Pethick J; Kibbi N; Hollestein L; Lavelle K; de Vere Hunt I; Turnbull C; Rous B; Husain A; Burn J; Lüchtenborg M; Santaniello F; McRonald F; Hardy S; Linos E; Venables Z; Rajan N
J Am Acad Dermatol; 2023 Dec; 89(6):1129-1135. PubMed ID: 37031776
[TBL] [Abstract][Full Text] [Related]
53. Well-concealed advanced duodenal carcinoma with Muir-Torre syndrome: a case report and review of literature.
Sugi T; Shimomura O; Hashimoto S; Takahashi K; Doi M; Miyazaki Y; Enomoto T; Akashi Y; Araki K; Oda T
Surg Case Rep; 2023 Feb; 9(1):24. PubMed ID: 36781705
[TBL] [Abstract][Full Text] [Related]
54. Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir-Torre Syndrome).
Miao Y; Kolb F; Tomasic G; Lupu J; Routier E; Robert C
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():74-76. PubMed ID: 34855250
[TBL] [Abstract][Full Text] [Related]
55. Muir-Torre syndrome in a haemodialysis patient.
Godfrey ED; Coward RA; Gharpuray-Pandit D; Lalloo F; McKirdy S; Woywodt A
Clin Kidney J; 2013 Aug; 6(4):414-7. PubMed ID: 27293570
[TBL] [Abstract][Full Text] [Related]
56. Muir-Torre Syndrome Associated Periocular Sebaceous Neoplasms: Screening Patterns in the Literature and in Clinical Practice.
Eiger-Moscovich M; Eagle RC; Shields CL; Racher H; Lally SE; Silkiss RZ; Shields JA; Milman T
Ocul Oncol Pathol; 2020 Aug; 6(4):226-237. PubMed ID: 33005611
[TBL] [Abstract][Full Text] [Related]
57. An Unexpected Esophageal Lesion in a Patient With Muir-Torre Syndrome.
Ellenberger N; Tränkenschuh W; Casper M
Gastroenterology; 2023 Feb; 164(2):187-190. PubMed ID: 35872071
[No Abstract] [Full Text] [Related]
58. Sebaceous carcinoma in a 54-year-old Black African man after cancer chemotherapy: a case report.
Olaofe OO; Adewara BA; Okongwu CC; Abdullahi YO
J Med Case Rep; 2024 Mar; 18(1):159. PubMed ID: 38500211
[TBL] [Abstract][Full Text] [Related]
59. Sebaceous Carcinoma Arising From Heterotopic Salivary Gland Tissue in a Patient With Muir-Torre Syndrome.
Syder NC; Rabi S; Hu JC
Dermatol Surg; 2021 Dec; 47(12):1659-1660. PubMed ID: 34608093
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
